# Interpace Biosciences, Inc. (IDXG)

Source: https://www.quantisnow.com/company/IDXG
Generated: 2026-10-29T19:00:18.392Z

- Ticker: IDXG
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: n/a
- SEC CIK: 0001054102
- Website: interpace.com

## About

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

## Latest IDXG news and filings

- 2026-10-15 15:53 UTC [SEC Form FWP] [SEC Form FWP filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-interpace-biosciences-inc-6747754)
- 2026-10-15 10:10 UTC [SEC Form 8-K] [SEC Form 8-K filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-interpace-biosciences-inc-6747111)
- 2026-10-01 01:00 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-interpace-biosciences-inc-6731205)
- 2026-09-24 23:48 UTC [SEC Form S-1] [SEC Form S-1 filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-interpace-biosciences-inc-6725921)
- 2026-09-17 19:45 UTC [SEC Form S-8] [SEC Form S-8 filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-interpace-biosciences-inc-6718949)
- 2026-08-27 12:30 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-amendments-to-articles-6696542)
- 2026-08-26 14:45 UTC [SEC Form 8-K] [Amendment: Interpace Biosciences, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-interpace-biosciences-inc-filed-sec-form-8-k-leadership-update-6695279)
- 2026-08-20 22:45 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-submission-of-matters-6690654)
- 2026-08-20 21:59 UTC [SEC Form 4] [CEO, President & Chairman Burnell Thomas W. converted options into 1,966,763 shares and covered exercise/tax liability with 581,718 shares, increasing direct ownership by 1,954% to 1,455,927 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/ceo-president-chairman-burnell-thomas-w-converted-options-into-1966763-6690483)
- 2026-08-20 21:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Aggarwal Vijay](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-aggarwal-vijay-6690383)
- 2026-08-20 21:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Keegan Joseph D](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-keegan-joseph-d-6690373)
- 2026-08-20 21:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Rocca Fortunato R.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rocca-fortunato-r-6690372)
- 2026-08-20 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Sullivan Stephen J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sullivan-stephen-j-6690352)
- 2026-08-20 20:59 UTC [SEC Form 4] [CFO & COO Mccarthy Christopher converted options into 277,009 shares, increasing direct ownership by 592% to 323,800 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-coo-mccarthy-christopher-converted-options-into-277009-shares-increasing-6690335)
- 2026-08-12 20:15 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6678019)
- 2026-08-10 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-interpace-biosciences-inc-6674226)
- 2026-08-10 20:35 UTC [Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results](https://www.quantisnow.com/insight/interpace-biosciences-announces-second-quarter-2026-financial-and-business-results-6674035)
- 2026-07-07 21:20 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-interpace-biosciences-inc-6630459)
- 2026-07-07 21:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-interpace-biosciences-inc-6630442)
- 2026-06-23 20:24 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-interpace-biosciences-inc-6612666)
- 2026-05-14 20:15 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6554122)
- 2026-05-12 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-interpace-biosciences-inc-6548509)
- 2026-05-12 20:06 UTC [Interpace Biosciences Announces First Quarter 2026 Financial and Business Results](https://www.quantisnow.com/insight/interpace-biosciences-announces-first-quarter-2026-financial-and-business-results-6547948)
- 2026-04-30 20:30 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-interpace-biosciences-inc-6524895)
- 2026-04-01 20:15 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6482042)
- 2026-03-30 21:38 UTC [SEC Form 10-K] [SEC Form 10-K filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-interpace-biosciences-inc-6477014)
- 2026-03-30 20:01 UTC [Dividends] [Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results](https://www.quantisnow.com/insight/interpace-biosciences-announces-fourth-quarter-and-full-year-2025-financial-6476496)
- 2026-02-17 21:05 UTC [SEC Form 4] [Large owner 1315 Capital Ii, L.P. converted options into 9,405,941 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-1315-capital-ii-lp-converted-options-into-9405941-6395872)
- 2026-02-04 23:46 UTC [SEC Form 4] [Large owner Ampersand 2018 Limited Partnership converted options into 13,861,386 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-ampersand-2018-limited-partnership-converted-options-into-13861386-6376072)
- 2026-01-20 14:05 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6353599)
- 2025-12-03 21:05 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-other-events-financial-6301466)
- 2025-11-12 21:45 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6275098)
- 2025-11-12 21:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-interpace-biosciences-inc-6274692)
- 2025-11-12 21:01 UTC [Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results](https://www.quantisnow.com/insight/interpace-biosciences-announces-third-quarter-2025-financial-and-business-results-6274104)
- 2025-09-15 13:15 UTC [Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting](https://www.quantisnow.com/insight/interpace-biosciences-presented-two-new-posters-at-the-2025-american-6200584)
- 2025-08-08 20:28 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6156528)
- 2025-08-07 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-interpace-biosciences-inc-6154370)
- 2025-08-07 20:05 UTC [Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results](https://www.quantisnow.com/insight/interpace-biosciences-announces-second-quarter-2025-financial-and-business-results-6153499)
- 2025-05-08 20:28 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Interpace Biosciences, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-interpace-biosciences-inc-6027990)
- 2025-05-08 20:25 UTC [SEC Form 8-K] [Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/interpace-biosciences-inc-filed-sec-form-8-k-results-of-operations-6027941)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IDXG
- RSS and alerts for IDXG: https://www.quantisnow.com/docs/rss-feeds.md